1259P - Phase II trial of metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer (MOVE TRIAL)

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer agents
Geriatric Oncology
Non-small-cell lung cancer
Biological therapy
Presenter Andrea Camerini
Citation Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349
Authors A. Camerini, C. Puccetti, S. Donati, C. Valsuani, M.C. Petrella, G. Tartarelli, P. Puccinelli, D. Amoroso
  • U.o.c. Oncologia Medica, Ospedale "Versilia", 55041 - Lido di Camaiore/IT



Metronomic oral vinorelbine could be a safe option for elderly patient with advanced non small cell lung cancer (NSCLC). Metronomic administration of chemotherapy leads to a cytostatic action shifting treatment target from cancer cell to tumor angiogenesis.


43 chemotherapy naive elderly (≥70 yrs) PS 0-2 patients with stage IIIB-IV NSCLC were prospectively recruited. Median age was 80 yrs (M/F 36/7) with predominantly squamous histology. PS distribution was 0-1(16)/2(27) with a median of 3 serious co-morbid illnesses. Study treatment consisted of oral vinorelbine 50mg three times weekly (Monday-Wednesday-Friday) continuously. Primary endpoints were overall response rate (ORR), clinical benefit (CB – disease response + stabilization >12 weeks) and safety. Health-related QoL (HRQoL) was also assessed. We conducted an exploratory time-course analysis of VEGF and thrombospondin-1 (TSP1) serum levels in a subgroup of patients.


Patients received a median of 5 (range 1-21) cycles with a total of 272 cycles delivered. ORR was 18.6% with 7 partial and 1 complete responses; 17/43 experienced stable disease lasting more than 12 weeks leading to an overall CB of 58.1%. Median time to progression was 5 (range 2-21) and median overall survival 9 (range 3-29) months. Treatment was well tolerated with rare G3/4 toxicity. Regardless of severity main toxicities observed were anemia in 44%, fatigue in 32.4%, and diarrhoea 10.5%. HRQoL scores did not significantly vary. Baseline VEGF levels were lower and showed a rapid increase during treatment in non-responders pts only while TSP1 levels did not change.


Metronomic oral vinorelbine is safe in elderly patients with advanced NSCLC with an interesting activity mainly consisting in long-term disease stabilization coupled with an optimal patient compliance.


All authors have declared no conflicts of interest.